Non-small-cell lung cancers: a heterogeneous set of diseases. - sprookjes - yvandenbroek - TriplyDB

Non-small-cell lung cancers: a heterogeneous set of diseases.

Non-small-cell lung cancers: a heterogeneous set of diseases.

http://www.wikidata.org/entity/Q38233321

about

Functions and mechanisms of long noncoding RNAs in lung cancer Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity Treatment of advanced squamous cell carcinoma of the lung: a review Advances in immunotherapy for treatment of lung cancer Molecular cancer prevention: Current status and future directions HaloTag technology: a versatile platform for biomedical applications KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors High Expression of Rab-like 3 (Rabl3) is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer via Repression of MAPK8/9/10-Mediated Autophagy Ceritinib: A primer for pharmacists.Defining a standard set of patient-centred outcomes for lung cancer.Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging Novel targeted therapies in chordoma: an update.KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-κB/Snail pathway Thioridazine has potent antitumor effects on lung cancer stem-like cells.Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment Prognostic significance of TCF21 mRNA expression in patients with lung adenocarcinoma.A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.DNA methylation profiling identifies the HOXA11 gene as an early diagnostic and prognostic molecular marker in human lung adenocarcinoma Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment.TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells Targeting lung cancer through inhibition of checkpoint kinases.A new mouse avatar model of non-small cell lung cancer.The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer Rhizoma Paridis Saponins Induces Cell Cycle Arrest and Apoptosis in Non-Small Cell Lung Carcinoma A549 Cells.Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).

P2860

Q26738672-DD8D01FE-9E5C-424F-A266-F6DCFC843F62 Q26769744-A73C7693-BE39-48C2-893E-E60722438F0E Q26775392-E769DFCE-E2D5-43B5-8A5F-EB329DFC8B6A Q26778790-108252E4-D051-42C0-8659-02C0F12319AB Q26797207-D372E88C-8234-405C-9C88-333CD230124E Q26997400-AC89C852-1955-4988-A652-B0E0CA440588 Q28069764-DDB9C7AE-E707-41FA-BA17-08E047AEE567 Q28086768-9FFFD8E1-ACC9-46D7-8171-8CB89D39197A Q28829201-670D5704-CBC5-4692-B7FE-A814EC286AD3 Q30244613-FFCB9982-7759-473D-86ED-F1DECB308353 Q30276400-4E174AEA-FF0C-4FEF-B1B7-D6907E853540 Q30851553-40D7F32B-60DA-4848-B1D3-EEC0735503B2 Q33275653-CD81351B-1BE7-4C0D-BB77-E6872E135CDE Q33566777-8C51776F-E556-431E-9BA1-EFF4374381C2 Q33568760-5EE03022-F6BD-46EA-B913-05EB5C4B9FF8 Q33599359-24336C7E-5BE2-4DED-A7AC-AABF9C5149CB Q33689527-2FC3B91D-2CC8-4FCD-B8EA-993ADF9DEB03 Q33700571-31B287DA-AE96-496F-BE5C-BC3C6F399EB5 Q33702017-5F75A228-5FB9-4851-9EB5-02BF813057FD Q33750741-4CB6604A-9125-4A29-8F03-D7E844FB7318 Q33763006-00FAD816-AAF8-4C7F-A5E5-B3CB57D6C334 Q33779169-F8831AE5-4196-4BD4-968F-451871DDCD93 Q33779373-6B82EA4D-9EF6-47AD-8E96-938C9C7ACB5D Q33824400-8FE3C5D2-8B3B-446E-80C7-703384531376 Q33911863-CF430912-929E-4919-A418-F83862F8819D Q34956692-5BAB74F8-E508-4A35-AD1D-91B5738A7727 Q35068068-38AB44B0-3598-4506-BCC8-FA003D003B17 Q35128547-588ED009-A463-4BF2-A22A-C6C258D8DDFE Q35141122-49350634-1069-4E3F-BBD2-EF549B1EC0C8 Q35237736-5F7961F7-EEFD-4CF4-8F98-7192D5F761FC Q35759218-5AACD1FD-05A1-49EF-8DF3-7454DF4BA16A Q35787132-BBDD210F-D3C5-45B8-B54C-8E1175F10290 Q35864528-2CBF54BB-8C98-4B28-9C38-2547B8CADB7B Q35865575-161AF15A-A7A9-4453-8732-F1FA9487D89A Q35928957-62E520A8-2EC9-43CE-ADB0-788D6BC5AFC7 Q35979222-4D473C13-34C4-4CD1-BB2D-8072A604DE80 Q36015618-8AAD8257-A69E-45E5-8D9A-1F43E000C7DD Q36060352-FE286F5C-CF83-4FFF-AC84-B005C7FED861 Q36090076-41804825-7B2B-48B5-BF0E-FD84ECF6E6A7 Q36140765-0DD57A2C-95E3-4EB0-A237-8C6CFC8163BB

P2860

Non-small-cell lung cancers: a heterogeneous set of diseases.

http://www.wikidata.org/entity/Q38233321

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Non-small-cell lung cancers: a heterogeneous set of diseases.

@en

type

label

Non-small-cell lung cancers: a heterogeneous set of diseases.

@en

prefLabel

Non-small-cell lung cancers: a heterogeneous set of diseases.

@en

P1433

Q38233321-9706D97C-9ED6-4182-B963-FF91BB8FC354

P1476

Q38233321-450F48F3-308F-4968-8EAA-DF6773CBDD6D

P2093

Q38233321-2E3E57EB-09F0-4C69-AFC3-D0CE592EB0DF

Q38233321-482BED5A-0E79-471B-AF0B-0B6B2D9F465A

Q38233321-55E7DD7D-3D03-4517-B9E5-511C0831A0F9

Q38233321-7C0C8D11-1E73-4B48-97E9-CB2D6FEEDD84

P2860

Q38233321-02E7AD5C-86FF-45DF-B20D-6EA4817A4C73

Q38233321-032A021F-FAF6-40C1-9994-107FF4CA45AB

Q38233321-050D007F-BF69-4293-893C-EF68E6FF0127

Q38233321-05860798-44A7-4F83-B274-84CA6D9E947A

Q38233321-05BDE578-B193-40BE-8512-B81A25FD3837

Q38233321-09461ABA-BEF6-4FA4-87AC-4657DB97DBA5

Q38233321-099511EF-79C0-4F1A-8827-F7BF463DF6BD

Q38233321-0A25DBDD-74B6-4FF9-8C6C-2B56D725EFCB

Q38233321-0AC270A8-CDFB-4E96-8616-1A162D2C0A98

Q38233321-0C31C1AC-1A64-48FC-8D7B-68C3E32D1E48

P2888

Q38233321-E463034C-9C12-4502-89E5-F584EB884250

P304

Q38233321-9BEA6946-97A1-4525-BEC5-D1D84BA48D1A

P31

Q38233321-494E7C11-B637-40BF-8817-4E2A725D05C6

P356

Q38233321-4378AFB2-12E5-4EFC-9A2B-7A7C0CFE8EDC

P407

Q38233321-6023B493-D643-44E0-84B9-12FC3273E956

P433

Q38233321-9F2798E5-5F63-4458-B9D2-0A13A29633BD

P478

Q38233321-BF8C5792-6A80-48DC-A1BE-CE79C26590D0

P50

Q38233321-4306A2E6-3138-49C7-AAAB-44C98B47FFDA

P577

Q38233321-ECDC3F5D-4451-4A9A-86A9-10BE79076845

P5875

Q38233321-EC022271-1043-429B-A4D8-C21B00EDFC4E

P6179

Q38233321-C342E3C6-7208-4B66-AD1A-37A7154BC60B

P698

Q38233321-0DD31A42-C998-44FC-963C-E7818542462C

P932

Q38233321-89F08EEC-2A10-4997-967A-7ED7FEEA4A56

P356

P1433

Nature Reviews Cancer

P1476

Non-small-cell lung cancers: a heterogeneous set of diseases.

@en

P2093

Carla F Kim

http://www.w3.org/2001/XMLSchema#string

Christine M Fillmore

http://www.w3.org/2001/XMLSchema#string

Peter S Hammerman

http://www.w3.org/2001/XMLSchema#string

Zhao Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence that SOX2 overexpression is oncogenic in the lung

Global cancer statistics

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Selective inhibition of BET bromodomains

Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

P2888

P304

535-546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRC3775

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264202337

http://www.w3.org/2001/XMLSchema#string

P6179

1028519566

http://www.w3.org/2001/XMLSchema#string

P698

25056707

http://www.w3.org/2001/XMLSchema#string

P932

5712844

http://www.w3.org/2001/XMLSchema#string